Treatments in Endocrinology

, Volume 4, Issue 3, pp 185–186

Spotlight on Paricalcitol in Secondary Hyperparathyroidism

Adis Spotlight

DOI: 10.2165/00024677-200504030-00007

Cite this article as:
Robinson, D.M. & Scott, L.J. Mol Diag Ther (2005) 4: 185. doi:10.2165/00024677-200504030-00007
  • 9 Downloads

Abstract

Paricalcitol (Zemplar®) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US pediatric, patients.

Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure. In well designed clinical trials, paricalcitol was as effective as calcitriol and as well tolerated in terms of the incidence of prolonged hypercalcemia and/or elevated calcium-phosphorus product (Ca × P). Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure.

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International Inc., YardleyYardleyUSA